All In Biotech

Drug Trial Radar · NCT05075408

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

258

Actual

Start

Mar 18, 2022

Primary completion

Jan 4, 2024

Study completion Jan 4, 2024

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Oct 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the efficacy of nemolizumab compared to placebo at reducing the intensity of pruritus after a 12-week treatment period in adult hemodialysis participants with moderate to severe pruritus.

Conditions

  • Chronic Kidney Disease Associated Moderate to Severe Pruritus

Interventions

  • NemolizumabDrug

    Participants received a loading dose of 60 mg nemolizumab at Baseline followed by 2 Subcutaneous (SC) injections for a total dose of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.

  • NemolizumabDrug

    Participants received 2 SC injections of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.

  • PlaceboDrug

    Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12Time frame: Baseline, Week 12

Locations

64 sites in 4 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site 9989

    Bakersfield, California

  • Galderma Investigational Site 9991

    Glendale, California

  • Galderma Investigational Site 7018

    Glendale, California

  • Galderma Investigational Site 7015

    La Palma, California

  • Galderma Investigational Site 9996

    Los Angeles, California

  • Galderma Investigational Site 9978

    Lynwood, California

  • Galderma Investigational Site 7017

    Riverside, California

  • Galderma Investigational Site 9973

    Tarzana, California

  • Galderma Investigational Site 7028

    Victorville, California

  • Galderma Investigational Site 9964

    Victorville, California

  • Galderma Investigational Site 7003

    Whittier, California

  • Galderma Investigational Site 9971

    Denver, Colorado

  • Galderma Investigational Site 9988

    Bloomfield, Connecticut

  • Galderma Investigational Site 9980

    Middlebury, Connecticut

  • Galderma Investigational Site 9970

    Boca Raton, Florida

  • Galderma Investigational Site 7037

    Coral Gables, Florida

  • Galderma Investigational Site 7026

    Hollywood, Florida

  • Galderma Investigational Site 9965

    Miami, Florida

  • Galderma Investigational Site7016

    Miami, Florida

  • Galderma Investigational Site 7032

    Sanford, Florida

  • Galderma Investigational Site 7004

    Tampa, Florida

  • Galderma Investigational Site 7025

    Tampa, Florida

  • Galderma Investigational Site 7027

    Columbus, Georgia

  • Galderma Investigational Site 9983

    Overland Park, Kansas

  • Galderma Investigational Site 9972

    Wichita, Kansas

  • Galderma Investigational Site 9963

    Roseville, Michigan

  • Galderma Investigational Site 7020

    Edina, Minnesota

  • Galderma Investigational Site 9982

    Minneapolis, Minnesota

  • Galderma Investigational Site 7035

    Kansas City, Missouri

  • Galderma Investigational Site 9962

    Las Vegas, Nevada

  • Galderma Investigational Site 7038

    Fresh Meadows, New York

  • Galderma Investigational Site 9998

    Great Neck, New York

  • Galderma Investigational Site 9995

    The Bronx, New York

  • Galderma Investigational Site 7007

    Winston-Salem, North Carolina

  • Galderma Investigational Site 9992

    Roseburg, Oregon

  • Galderma Investigational Site 9999

    Spartanburg, South Carolina

  • Galderma Investigational Site 9967

    Chattanooga, Tennessee

  • Galderma Investigational Site 7039

    Arlington, Texas

  • Galderma Investigational Site 7040

    Dallas, Texas

  • Galderma Investigational Site 9966

    El Paso, Texas

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.